公开(公告)号：EP4361152A1

公开(公告)日：2024-05-01

申请号：EP22827576.4

申请日：2022-06-21

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. ,  Shouyao Holdings (Beijing) Co., Ltd. ,  Lianyungang Runzhong Pharmaceutical Co., Ltd.

发明人： TU, Lifan ,  ZHANG, Xiquan ,  WANG, Xunqiang ,  YU, Ding ,  HUANG, Jianqiang

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P37/06

CPC分类号： C07D487/04 ,  A61K31/519 ,  A61P37/06

摘要： The present invention relates to the use of a pyrrolopyrimidine compound and a pharmaceutical composition thereof for treating chronic graft versus host disease, and particularly relates to the use of a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof for treating chronic graft versus host disease.

公开(公告)号：EP4119562A1

公开(公告)日：2023-01-18

申请号：EP21767840.8

申请日：2021-03-09

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. ,  Lianyungang Runzhong Pharmaceutical Co., Ltd. ,  Shouyao Holdings (Beijing) Co., Ltd.

发明人： LIANG, Hongming ,  ZHANG, Xiquan ,  WANG, Xunqiang ,  YU, Ding ,  WANG, Dong ,  GE, Qi ,  WANG, Zhao ,  WANG, Yini

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P7/00

摘要： The present invention relates to use of a pyrrolopyrimidine compound for treating hemophagocytic syndrome, and particularly relates to use of a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof for treating hemophagocytic syndrome.

公开(公告)号：EP3476841A1

公开(公告)日：2019-05-01

申请号：EP17814745.0

申请日：2017-06-23

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ,  Lianyungang Runzhong Pharmaceutical Co., Ltd. ,  Centaurus BioPharma Co., Ltd.

发明人： ZHU, Yizhong ,  TANG, Jianqiu ,  LIU, Fei ,  ZHANG, Xiquan ,  GU, Hongmei ,  ZHU, Bo ,  WANG, Lulu ,  TANG, Song ,  ZHANG, Yanyang

IPC分类号： C07D403/04 ,  A61K31/506 ,  A61P35/00 ,  A61P35/02

摘要： The present application belongs to the field of medicinal chemistry, and relates to crystals of an aniline pyrimidine compound serving as an EGFR inhibitor. Specifically, the present application relates to crystal A, crystal B and crystal C of N-(2-((2-(dimethyl amino)ethyl)(methyl)amino)-4-methoxy-5-(4-(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-1-base)pyrimidine-2-base amino)phenyl)acrylamide (formula I) hydrochloride, and also relates to the method for preparing the crystal A, the crystal B and the crystal C, a crystal composition comprising the crystal A, the crystal B, and the crystal C, a pharmaceutical composition comprising the crystal A, the crystal B and the crystal C or the crystal composition thereof, and medical uses thereof. The crystal A, the crystal B and the crystal C in the present application has the advantages of high purity, high crystallization degree, good stability and the like.

公开(公告)号：EP3330258A1

公开(公告)日：2018-06-06

申请号：EP16829878.4

申请日：2016-07-29

申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd ,  Lianyungang Runzhong Pharmaceutical Co., Ltd. ,  Centaurus BioPharma Co., Ltd.

发明人： ZHAO, Na ,  WANG, Shulong ,  LIU, Xijie ,  HU, Yuandong ,  ZHANG, Hui ,  LUO, Hong ,  PENG, Yong ,  HAN, Yongxin ,  ZHANG, Xiquan ,  XU, Hongjiang

IPC分类号： C07D251/18 ,  C07D251/26 ,  A61K31/53 ,  A61P35/00

CPC分类号： A61K31/53 ,  C07D251/18 ,  C07D251/26

摘要： Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.

公开(公告)号：EP3272746B1

公开(公告)日：2019-12-25

申请号：EP16767717.8

申请日：2016-03-18

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ,  Centaurus BioPharma Co., Ltd. ,  Lianyungang Runzhong Pharmaceutical Co., Ltd.

发明人： ZHANG, Xiquan ,  TANG, Song ,  FENG, Weiwei ,  TIAN, Xin ,  CHEN, Zhilin ,  GU, Hongmei ,  XU, Hongjiang ,  LIU, Fei

IPC分类号： C07D403/12 ,  C07D401/12 ,  C07D405/14 ,  A61K31/517 ,  A61K31/5377 ,  A61P35/00 ,  A61K31/4427 ,  A61K45/06 ,  C07D239/94 ,  C07D211/40

公开(公告)号：EP3498704A1

公开(公告)日：2019-06-19

申请号：EP17838796.5

申请日：2017-08-11

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ,  Lianyungang Runzhong Pharmaceutical Co., Ltd. ,  Centaurus BioPharma Co., Ltd.

发明人： SANG, Guangming ,  LIU, Lin ,  ZHANG, Aiming ,  QIAO, Jiabin ,  GUO, Xiaopeng ,  ZHANG, Xiquan ,  XIA, Chunguang

IPC分类号： C07D405/04 ,  A61K31/4035 ,  A61P5/50 ,  A61P3/00 ,  A61P35/00 ,  A61P25/00 ,  A61P3/12

摘要： The present application relates a crystal of a compound represented by Formula (I), a salt thereof, and a crystal of the salt thereof, a method for preparing the crystal of the compound represented by Formula (I), the salt thereof, and the crystal of the salt thereof, a crystal comprising the compound represented by Formula (I), a crystal composition comprising the crystal of the salt thereof, a pharmaceutical composition thereof, and medical uses thereof.

公开(公告)号：EP3473626A1

公开(公告)日：2019-04-24

申请号：EP17812741.1

申请日：2017-06-15

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ,  Lianyungang Runzhong Pharmaceutical Co., Ltd. ,  Centaurus BioPharma Co., Ltd.

发明人： ZHOU, Zhou ,  ZHANG, Aiming ,  ZHANG, Xiquan ,  YAO, Huadong

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  A61P35/00

摘要： The present application relates to the field of pharmaceutical chemistry. The application specifically relates to a crystal form A and crystal form B of a pyrrolopyrimidine (formula I) for preparing a JAK inhibitor. The application further relates to a method for preparing the crystal form A and crystal form B, a crystalline composition comprising the crystal form A or crystal form B, a pharmaceutical composition comprising the crystal form A, crystal form B, or crystalline composition, and a pharmaceutical application of the pharmaceutical composition, the crystal form A, and the crystal form B. The crystal form A and crystal form B of the application has the advantages of high purity, high crystallinity, and good stability.

公开(公告)号：EP3473625A1

公开(公告)日：2019-04-24

申请号：EP17812738.7

申请日：2017-06-15

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ,  Lianyungang Runzhong Pharmaceutical Co., Ltd. ,  Centaurus BioPharma Co., Ltd.

发明人： ZHANG, Xiquan ,  ZHANG, Aiming ,  ZHOU, Zhou ,  YAO, Huadong ,  XIE, Jie

IPC分类号： C07D487/04

摘要： Provided are a preparation method for a chiral pyrrolopyrimidine compound and a related intermediate. In the method, a compound of formula A and a compound of formula 6 or a salt thereof are reacted to obtain a compound of formula 7 or a compound of formula 14, and a compound of formula I is prepared from the compound of formula 7 or the compound of formula 14. Also provided are the intermediate used, a preparation method for the intermediate and a use of the intermediate in the preparation of the compound of formula I. The preparation method has characteristics such as brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and a convenient post-treatment. The method avoids using an expensive asymmetric reaction catalyst, and is suitable for industrial production.

公开(公告)号：EP3330263A1

公开(公告)日：2018-06-06

申请号：EP16829888.3

申请日：2016-07-29

申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd ,  Lianyungang Runzhong Pharmaceutical Co., Ltd. ,  Centaurus BioPharma Co., Ltd.

发明人： WANG, Shulong ,  ZHAO, Na ,  LIU, Xijie ,  HU, Yuandong ,  ZHANG, Hui ,  LUO, Hong ,  PENG, Yong ,  XIAO, Dengming ,  HAN, Yongxin ,  ZHANG, Xiquan ,  TIAN, Xin

IPC分类号： C07D333/24 ,  C07D409/12 ,  C07D213/56 ,  C07C275/42 ,  C07D231/12 ,  C07D409/10 ,  C07D333/20 ,  A61P35/00 ,  A61P35/02

摘要： The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers.

公开(公告)号：EP3176160A1

公开(公告)日：2017-06-07

申请号：EP15826817.7

申请日：2015-07-31

申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd ,  Lianyungang Runzhong Pharmaceutical Co., Ltd. ,  Centaurus BioPharma Co., Ltd.

发明人： GONG, Feng ,  LI, Xinlu ,  ZHAO, Rui ,  ZHANG, Xiquan ,  XU, Xinhe ,  LIU, Xijie ,  XIAO, Dengming ,  HAN, Yongxin

IPC分类号： C07D401/14 ,  C07D213/73 ,  A61K31/496 ,  A61K31/444 ,  A61P35/00

CPC分类号： C07D401/14 ,  A61K31/444 ,  A61K31/496 ,  C07D213/73

摘要： The present invention discloses pharmaceutically acceptable acid salts of pyridine-substituted 2-aminopyridine derivatives as protein kinase inhibitors, preparation methods, pharmaceutical compositions thereof, and use thereof for the treatment of diseases associated with protein kinase.

摘要翻译： 本发明公开了作为蛋白激酶抑制剂的吡啶取代的2-氨基吡啶衍生物的药学上可接受的酸式盐，其制备方法，药物组合物及其用于治疗与蛋白激酶相关的疾病的用途。